Synergy Pharmaceuticals to Present at Jefferies 2016 London Healthcare Conference
November 10 2016 - 9:30AM
Business Wire
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the
company will present a corporate update at the Jefferies London
Healthcare Conference on Wednesday, November 16, 2016 at 8:00 a.m.
GMT.
A live webcast of the presentation will be accessible through
the Investor Relations section of the company’s website at
www.synergypharma.com. A replay of the webcast will be available on
Synergy’s website for 60 days following the conference.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the
development and commercialization of novel gastrointestinal (GI)
therapies. The company has pioneered discovery, research and
development efforts around analogs of uroguanylin, a naturally
occurring human GI peptide, for the treatment of GI diseases and
disorders. Synergy discovered, is developing and controls 100%
worldwide rights to its proprietary uroguanylin analog platform
that includes two lead product candidates – plecanatide and
dolcanatide. Plecanatide is Synergy’s first uroguanylin analog
currently being evaluated for use as a once-daily tablet for
chronic idiopathic constipation and irritable bowel syndrome with
constipation. Dolcanatide is Synergy’s second uroguanylin analog
currently being explored for ulcerative colitis. For more
information, please visit www.synergypharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161110005861/en/
Synergy Pharmaceuticals Inc.Gem Hopkins, 212-584-7610VP,
Investor Relations and Corporate
Communicationsghopkins@synergypharma.com
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Historical Stock Chart
From Apr 2024 to May 2024
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Historical Stock Chart
From May 2023 to May 2024